Drug
Remestemcel-l clinical trials
Also written Prochymal®.
Keep track of what changes. Save the remestemcel-l studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2015 | 2 |
| 2020 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 3
Mesoblast, Inc. (12) · The Cleveland Clinic (2) · Mesoblast, Ltd. (1) · Icahn School of Medicine at Mount Sinai (1)
Studies
Open first, then newest update. How each study uses remestemcel-l is read from its arms, and is right about nine times in ten.
Testing it · 16
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host DiseaseNot yet recruitingPhase 3Mesoblast, Ltd.NCT07568535Written as Remestemcel-L-rknd
- Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)TerminatedPhase 1/2The Cleveland ClinicNCT04543994Written as Remestemcel-L
- Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's ColitisTerminatedPhase 1/2The Cleveland ClinicNCT04548583Written as Remestemcel-L
- Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's DiseaseCompletedPhase 3Mesoblast, Inc.NCT00482092Written as Prochymal®
- Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's DiseaseCompletedPhase 3Mesoblast, Inc.NCT01233960Written as Prochymal®
- PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)CompletedPhase 2Mesoblast, Inc.NCT00690066Written as PROCHYMAL®
- PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2Mesoblast, Inc.NCT00683722Written as Prochymal™
- Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)CompletedPhase 2Mesoblast, Inc.NCT00877903Written as Prochymal®
- Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD ParticipantsCompletedPhase 2Mesoblast, Inc.NCT00284986Written as Prochymal
- MSCs in COVID-19 ARDSTerminatedPhase 3Icahn School of Medicine at Mount SinaiNCT04371393Written as Remestemcel-L
- A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)CompletedPhase 3Mesoblast, Inc.NCT02336230Written as remestemcel-L
- Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHDCompletedPhase 3Mesoblast, Inc.NCT02652130Written as Remestemcel-L
- Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)CompletedPhase 3Mesoblast, Inc.NCT00366145Written as Prochymal®
- Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)CompletedPhase 2Mesoblast, Inc.NCT00136903Written as Prochymal® - 2 Million cells/kg
- Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)CompletedPhase 3Mesoblast, Inc.NCT00562497Written as Prochymal®
- Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's DiseaseCompletedPhase 2Mesoblast, Inc.NCT00294112Written as Prochymal™ adult human mesenchymal stem cells
Codes
What other systems call remestemcel-l · ClinicalTrials.gg INT001463
- MeSH (NLM) C000711674remestemcel-lConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) H57D26Z9YKREMESTEMCEL-LConfirmed FDA, NLM
- NCI Thesaurus C67082Remestemcel-LOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711674 | remestemcel-l | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | H57D26Z9YK | REMESTEMCEL-L | Confirmed FDA, NLM |
| NCI Thesaurus | C67082 | Remestemcel-L | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.